Literature DB >> 30443702

Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis.

Shanshan Wu1, Zhirong Yang2,3, Jialing Zhou1, Na Zeng1, Zhiying He1, Siyan Zhan4, Jidong Jia1,5, Hong You6,7.   

Abstract

BACKGROUND AND AIMS: Non-invasive fibrosis assessment has been highly recommended in many liver diseases. However, comparative diagnostic accuracy of laboratory markers, ultrasound and magnetic resonance elastography (MRE) for fibrosis in autoimmune hepatitis (AIH) patients has not been established.
METHODS: Medline, Embase and Cochrane Library were searched. Primary outcome was significant fibrosis (SF), advanced fibrosis (AF) and cirrhosis, defined as Metavir stage F ≥ 2, F ≥ 3 and F = 4 according to liver biopsy. Hierarchical summary receiver operating characteristic curve (ROC) model was used to evaluate diagnostic accuracy of non-invasive methods. Summary area under ROC (AUROC) and diagnostic odds ratio (DOR) with 95% confidence interval (CI) were calculated. The Grading of Recommendations Assessment, Development and Evaluation system was used to assess quality of evidence.
RESULTS: Overall, 16 studies with 861 patients were included, comparing aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), aspartate aminotransferase/alanine aminotransferase ratio, transient elastography (TE), acoustic radiation force impulse, shear wave elastography and MRE versus liver biopsy. Among all non-invasive markers, TE had good performance for fibrosis staging. Summary AUROCs and DORs of TE were 0.90 (95% CI 0.87, 0.92) and 23.7, 0.91 (95% CI 0.89, 0.93) and 31.6, 0.89 (95% CI 0.86, 0.92) and 80.5 for staging SF, AF and cirrhosis, whereas APRI and FIB-4 showed poor performance for detecting AF (DOR, 4.6 and 4.7) and cirrhosis (DOR, 5.5 and 12.9).
CONCLUSIONS: TE performs well to stage liver fibrosis in patients with AIH, compared with other laboratory non-invasive indexes. Nevertheless, diagnostic accuracy of APRI and FIB-4 is poor.

Entities:  

Keywords:  Autoimmune hepatitis; Liver fibrosis; Non-invasive methods; Transient elastography

Mesh:

Year:  2018        PMID: 30443702     DOI: 10.1007/s12072-018-9907-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  28 in total

1.  Diagnosis and management of autoimmune hepatitis.

Authors:  Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  Sample size calculation should be performed for design accuracy in diagnostic test studies.

Authors:  Antoine Flahault; Michel Cadilhac; Guy Thomas
Journal:  J Clin Epidemiol       Date:  2005-08       Impact factor: 6.437

3.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

4.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

5.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

Authors:  Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

6.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

7.  Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis.

Authors:  Aldo J Montano-Loza; Herschel A Carpenter; Albert J Czaja
Journal:  Am J Gastroenterol       Date:  2008-06-28       Impact factor: 10.864

8.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.

Authors:  Albert J Czaja; Herschel A Carpenter
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

10.  Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening.

Authors:  Andrew D Yeoman; Thawab Al-Chalabi; John B Karani; Alberto Quaglia; John Devlin; Giorgina Mieli-Vergani; Adrian Bomford; John G O'Grady; Phillip M Harrison; Michael A Heneghan
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

View more
  8 in total

1.  Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease.

Authors:  Andrea Sonaglioni; Federica Cerini; Antonio Cerrone; Lorenzo Argiento; Gian Luigi Nicolosi; Elisabetta Rigamonti; Michele Lombardo; Maria Grazia Rumi; Mauro Viganò
Journal:  Intern Emerg Med       Date:  2022-03-17       Impact factor: 5.472

2.  Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Patients With Autoimmune Hepatitis: A Meta-Analysis.

Authors:  Bingtian Dong; Yuping Chen; Guorong Lyu; Xiaocen Yang
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 3.  Quantitative magnetic resonance imaging for chronic liver disease.

Authors:  Guilherme Moura Cunha; Patrick J Navin; Kathryn J Fowler; Sudhakar K Venkatesh; Richard L Ehman; Claude B Sirlin
Journal:  Br J Radiol       Date:  2021-02-26       Impact factor: 3.629

4.  Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease.

Authors:  Matthias Buechter; Sarah Kersting; Guido Gerken; Alisan Kahraman
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

5.  The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis.

Authors:  Yuanqiang Lin; Hequn Li; Chunxiang Jin; Hui Wang; Bo Jiang
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

Review 6.  Recent updates on the management of autoimmune hepatitis.

Authors:  Atsumasa Komori
Journal:  Clin Mol Hepatol       Date:  2020-12-10

7.  Usefulness of 2D shear wave elastography for the evaluation of hepatic fibrosis and treatment response in patients with autoimmune hepatitis.

Authors:  Eun Gyu Soh; Young Hwan Lee; Youe Ree Kim; Kwon-Ha Yoon; Keum Ha Choi
Journal:  Ultrasonography       Date:  2022-04-03

8.  Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis.

Authors:  Sai Chalasani; Karan Mathur; Nicole Shammas; Eric Orman; Raj Vuppalanchi; Craig Lammert
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.